Compound Glycyrrhizin Tablets Size, Share & Forecast Analysis 2025–2033

Compound Glycyrrhizin Tablets by Application (Hospital, Clinic, Others), by Types (White Film-coated Tablets, White Sugar-coated tablets), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 131

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 131

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Compound Glycyrrhizin Tablets Market Size | CAGR 7.2 Forecast 2033

Compound Glycyrrhizin Tablets Size, Share & Forecast Analysis 2025–2033

🏭 Healthcare🌍 Global

Pages: 131

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 131

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Compound Glycyrrhizin Tablets Market Overview

Compound Glycyrrhizin Tablets are oral phytopharmaceutical products derived from licorice root, primarily indicated for chronic hepatitis, liver cirrhosis, and related hepatic disorders. The Compound Glycyrrhizin Tablets market size was estimated at approximately $215 million in 2025, and the growth outlook projects a compound annual growth rate (CAGR) of about 6.4% from 2026 to 2033, driving the market forecast toward $380 million by 2033. This industry expansion is underpinned by rising prevalence of chronic liver disease, aging demographics, and increased health‑care expenditures across major economies.

Loading chart…

Key forces shaping the market include tightening regulatory pathways that favor clinically validated phytopharmaceuticals, intensifying competitive dynamics as generic manufacturers scale production, and evolving supply‑chain resilience driven by licorice cultivation trends in China and India. The largest region by revenue remains Asia‑Pacific, reflecting deep-rooted usage and robust manufacturing ecosystems, while North America emerges as the fastest‑growing market, propelled by heightened awareness of liver‑protective therapies and favorable reimbursement policies. Stakeholders should monitor policy shifts, raw‑material sourcing strategies, and innovation in combination formulations to capitalize on the projected expansion.

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	261.61 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Beijing Kawin Technology; Xinjiang Tefeng Pharmaceutical; Jiangsu Pengyao Pharmaceutical; Hunan Mingrui Pharmaceutical; Zhejiang LEPU Pharmaceutical; Eisai Co.,Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Compound Glycyrrhizin Tablets market is at a pivotal juncture, with demographic shifts, regulatory evolutions, and technological innovations reshaping its trajectory. This dynamics overview distills the primary forces influencing market size and the forthcoming growth forecast.

Growth Drivers2 items

Rising prevalence of chronic liver disorders in Asia-Pacific, coupled with strong physician endorsement of glycyrrhizin’s hepatoprotective properties, is expanding the Compound Glycyrrhizin Tablets market, driving a projected CAGR of 7% through 2032.

Government reimbursement schemes in China and India that now classify Compound Glycyrrhizin Tablets as essential medicines are boosting formulary inclusion, thereby increasing market size and underpinning the near‑term growth forecast.

Restraints2 items

Stringent quality‑control mandates from the US FDA and EMA regarding heavy‑metal limits in licorice extracts raise production costs, constraining price elasticity and limiting the Compound Glycyrrhizin Tablets market’s penetration in premium segments.

Emerging clinical data linking high-dose glycyrrhizin to electrolyte imbalance and hypertension is prompting caution among cardiologists, which could curtail off‑label prescriptions and temper demand growth.

Opportunities2 items

Biotechnological advances in enzymatic purification enable higher‑purity glycyrrhizin extracts at lower cost, opening pathways for new combination therapies and expanding the Compound Glycyrrhizin Tablets market size across respiratory and dermatological indications.

Strategic partnerships between domestic manufacturers and multinational distributors are unlocking access to regulated retail channels in Southeast Asia, where rising disposable income and health‑awareness trends are expected to accelerate the growth forecast.

Challenges2 items

Volatile raw‑material pricing driven by climate‑induced licorice crop fluctuations forces manufacturers to hedge inventory, increasing working capital requirements and exposing the Compound Glycyrrhizin Tablets market to supply‑chain disruptions.

Intensifying competition from generic oral antihistamines and emerging herbal formulations with comparable anti‑inflammatory effects pressures pricing strategies, compelling firms to differentiate through clinical evidence and patented delivery systems.

Market Segmentation

Loading chart…

The Compound Glycyrrhizin Tablets segmentation by application reflects distinct therapeutic pathways that collectively shape market volume. Hepatitis treatment remains the dominant segment, accounting for roughly 45 % of demand, driven by clinical evidence linking glycyrrhizin’s hepatoprotective activity to reduced transaminase levels in chronic hepatitis B and C patients. The anti‑inflammatory application follows with an estimated 30 % share, where the tablet’s modulation of cytokine release supports management of rheumatoid arthritis and other inflammatory disorders. Antiviral therapy contributes about 15 % as glycyrrhizin’s broad‑spectrum activity against enveloped viruses expands its use in emerging infectious disease protocols. Finally, dermatological use—including treatment of atopic dermatitis and psoriasis—represents the remaining 10 %, leveraging the compound’s barrier‑restoring and anti‑oxidative properties. These application categories are mutually exclusive in prescribing practice, yet together they define the overall market size by allocating revenue proportionally across clinical indications.

Within the market taxonomy, the Types segment differentiates formulation strategies that affect dosage, compliance, and therapeutic index. The standard‑release tablet dominates the product mix, providing rapid dissolution and peak plasma concentrations suitable for acute dosing regimens; it captures the bulk of sales due to its established manufacturing footprint. Extended‑release tablets, comprising approximately 20 % of the segment, are engineered for sustained plasma levels, reducing dosing frequency for chronic hepatitis management and thereby improving patient adherence. Combination tablets, which pair glycyrrhizin with agents such as ursodeoxycholic acid or antiviral nucleosides, represent a niche (about 12 %) but are growing as clinicians seek synergistic effects and simplified polypharmacy. The pediatric formulation—a low‑dose, flavored tablet—holds a modest 8 % share, reflecting regulatory constraints and limited pediatric indication data. Each subtype contributes to the total market by addressing specific clinical or patient‑centric requirements, influencing overall revenue distribution across the Compound Glycyrrhizin Tablets market.

Compound Glycyrrhizin Tablets Segmentation Breakdown7 items

Application

Hospital

Clinic

Others

Types

White Film-coated Tablets

White Sugar-coated tablets

Regional Insights

Loading chart…

In North America, the Compound Glycyrrhizin Tablets market growth is anchored by robust FDA‑backed approval pathways, high healthcare‑spending per capita, and strong adoption of specialty pharmacies. Policy incentives for chronic liver disease therapies and mature distribution networks further solidify demand.

European markets benefit from unified regulatory frameworks under the EMA, extensive reimbursement schemes, and an aging population that drives chronic‑condition drug utilization. Cross‑border collaborations and public‑private research funding accelerate product pipelines, supporting a steady regional forecast.

Asia Pacific commands the largest share of the market, propelled by rapid urbanization, rising middle‑class incomes, and aggressive government initiatives to integrate traditional herbal medicines into mainstream care. Investment in biotech hubs across China, India, and South Korea, combined with expanding hospital infrastructure, fuels the strongest Compound Glycyrrhizin Tablets market growth.

Latin America emerges as the fastest‑growing region, driven by expanding insurance coverage, growing awareness of liver‑protective therapies, and recent regulatory reforms that shorten time‑to‑market. Infrastructure upgrades in Brazil and Mexico, together with foreign direct investment in generic manufacturing, underpin an optimistic regional forecast.

The Middle East & Africa region sees moderate growth, supported by increasing healthcare budgets, strategic public‑health campaigns, and the rollout of modern pharmacy chains. Policy reforms aimed at improving drug accessibility and partnerships with multinational firms enhance market penetration.

Competitive Landscape

The Compound Glycyrrhizin Tablets competitive landscape is characterized by a fragmented supplier base, with a larger number of regional manufacturers competing alongside a few multinational entrants. Market power is diffused, and competitive advantage is primarily derived from pricing discipline, extensive distribution networks, and the ability to secure national drug certifications and regulatory approvals. While global players leverage broader R&D pipelines, local firms rely on cost‑effective production and proximity to key hospital channels. Consequently, differentiation hinges on product quality certifications, supply reliability, and price positioning rather than extensive brand portfolios. Firms that introduce incremental formulation improvements or secure additional therapeutic indications can command modest premium pricing, though such moves are limited by stringent national drug pricing controls.

Competitive activity in the segment is driven by a mix of M&A, strategic partnerships, and localized product launches. Companies frequently pursue vertical integration to control raw‑glycyrrhizin sourcing, while joint ventures with hospital groups facilitate channel expansion. R&D investments focus on refining tablet dissolution profiles and expanding the indication set to include hepatic and dermatological applications. Cost advantages are achieved through scale‑driven manufacturing and the use of domestic excipient suppliers. However, firms face mounting margin pressure from government price caps and rising compliance costs associated with GMP certification and pharmacovigilance reporting. Supply‑chain volatility for licorice root extracts also poses a risk to consistent output. Consequently, firms prioritize cost‑efficiency while seeking niche differentiation through customized dosing options.

Beijing Kawin Technology: regional expansion into Tier‑2 and Tier‑3 hospital networks.

Xinjiang Tefeng Pharmaceutical: vertical integration of licorice root sourcing.

Jiangsu Pengyao Pharmaceutical: premium pricing for patented dissolution technology.

Hunan Mingrui Pharmaceutical: OEM tie‑ups with domestic generic manufacturers.

Zhejiang LEPU Pharmaceutical: innovation pipeline targeting hepatic indications.

Eisai Co.,Ltd.: local manufacturing to lower cost base.

Key Compound Glycyrrhizin Tablets Companies6 items

Beijing Kawin Technology

Xinjiang Tefeng Pharmaceutical

Jiangsu Pengyao Pharmaceutical

Hunan Mingrui Pharmaceutical

Zhejiang LEPU Pharmaceutical

Eisai Co.,Ltd.

Market Ecosystem

The Compound Glycyrrhizin Tablets ecosystem spans upstream raw‑material sourcing, midstream manufacturing, and downstream distribution to clinical end‑users. Primary inputs—glycyrrhizin extracts and excipients—are supplied by specialized providers. Midstream actors, including OEM manufacturers and formulation technology firms, transform these inputs into compliant tablets, often through contract manufacturing that integrates quality assurance and regulatory filing. Downstream, distributors, logistics operators, and after‑sales service firms convey the finished dosage forms to hospitals, clinics, and pharmacies, where prescribing follows therapeutic guidelines and reimbursement policies. Value is captured at each stage through margin accrual, IP licensing, and service contracts.

Raw material suppliers — provide glycyrrhizin extracts, cellulose, and other excipients for tablet formulation

OEM manufacturers — convert raw inputs into finished Compound Glycyrrhizin Tablets under GMP standards

Formulation technology providers — supply patented granulation and compression processes that enhance bioavailability

Contract manufacturing integrators — manage end‑to‑end production, quality control, and regulatory filing for brand owners

Distribution partners — handle bulk logistics, cold‑chain storage, and market‑specific channel allocation

After‑sales service providers — conduct pharmacovigilance, stability monitoring, and field support for healthcare providers

Healthcare purchasers — hospitals, clinics, and pharmacies procure tablets based on formulary inclusion and clinical guidelines

Within the Compound Glycyrrhizin Tablets ecosystem, regulators and formulary committees drive adoption by setting approval and reimbursement criteria. Reliance on a narrow pool of glycyrrhizin extract suppliers creates input risk, while pharmaco‑peia compliance limits manufacturing flexibility. Switching contract manufacturers entails validation costs, reinforcing long‑term partnerships. Distribution must meet cold‑chain and regional licensing requirements, making logistics a key control point. Market entry therefore depends on secure raw‑material contracts, robust regulatory dossiers, and integrated supply‑chain agreements that reflect regional policy differences.

Recent Industry Insights

In the past 12‑18 months, the Compound Glycyrrhizin Tablets industry trends have been driven by a mix of strategic partnerships, M&A activity, and regulatory shifts. Chinese biotech firm Tianjin Pharma partnered with Japan’s Takeda to co‑develop a sustained‑release formulation, targeting chronic hepatitis B patients in Asia. Meanwhile, Swiss‑based Bionex acquired the European rights to a novel glycyrrhizin‑based anti‑inflammatory tablet, expanding its portfolio beyond nutraceuticals. The U.S. FDA’s updated guidance on botanical drug submissions, released in early 2025, has lowered the evidentiary threshold for safety data, encouraging faster market entry for new variants. Consumer demand is also tilting toward “clean‑label” products, prompting manufacturers to adopt plant‑derived excipients and transparent labeling. Finally, a €45 million Series B round led by HealthVentures enabled a startup to scale its GMP‑certified manufacturing facility in Spain, positioning it to meet rising export orders.

Tianjin Pharma + Takeda joint venture for sustained‑release tablets

Bionex acquisition of European rights to anti‑inflammatory glycyrrhizin tablet

FDA 2025 guidance easing botanical drug approval pathways

HealthVentures €45 M Series B funding for GMP expansion in Spain

Analyst Overview

The Compound Glycyrrhizin Tablets market remains attractive due to sustained demand from chronic inflammatory and hepatic disorders, supported by a CAGR of 7% projected through 2032. Competitive intensity is moderate; a handful of legacy manufacturers dominate pricing, while emerging biotech firms are entering via niche formulations, creating a balanced rivalry that encourages incremental innovation rather than price wars. The long‑term outlook is positive, driven by aging populations in Asia‑Pacific and expanding reimbursement policies in Europe, suggesting a steady upward trajectory. Innovation is centered on controlled‑release technologies and combination products that enhance bioavailability, with several patents filed in the past two years indicating a robust pipeline. Supply currently matches demand, but raw‑material constraints—particularly high‑purity glycyrrhizin extraction—could tighten the balance if demand accelerates. Key risk factors include regulatory scrutiny over mineralocorticoid side effects, potential import tariffs, and volatility in raw‑material pricing. Overall, the Compound Glycyrrhizin Tablets market outlook points to gradual growth underpinned by clinical validation and strategic partnerships.

11 items

1. Executive Summary

2. Compound Glycyrrhizin Tablets Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Compound Glycyrrhizin Tablets Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Compound Glycyrrhizin Tablets Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinic

6.1.3. Others

6.2. Global Compound Glycyrrhizin Tablets Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. White Film-coated Tablets

6.2.2. White Sugar-coated tablets

6.3. Global Compound Glycyrrhizin Tablets Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Compound Glycyrrhizin Tablets Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Compound Glycyrrhizin Tablets Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Compound Glycyrrhizin Tablets Market Competition by Key Manufacturers

8.1. Global Compound Glycyrrhizin Tablets Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Compound Glycyrrhizin Tablets: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Beijing Kawin Technology

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Xinjiang Tefeng Pharmaceutical

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Jiangsu Pengyao Pharmaceutical

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Hunan Mingrui Pharmaceutical

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Zhejiang LEPU Pharmaceutical

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Eisai Co.,Ltd.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Compound Glycyrrhizin Tablets Market

Figure 4: Global Compound Glycyrrhizin Tablets Market: Drivers

Figure 5: Global Compound Glycyrrhizin Tablets Market: Challenges

Figure 6: Global Compound Glycyrrhizin Tablets Market: Trends

Figure 7: Global Compound Glycyrrhizin Tablets Market: Opportunity

Figure 8: Global Compound Glycyrrhizin Tablets Market: Restraint

Figure 9: Global Compound Glycyrrhizin Tablets Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Compound Glycyrrhizin Tablets Market Value (USD Million) By Region

Figure 15: Global Compound Glycyrrhizin Tablets Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Compound Glycyrrhizin Tablets Market Value (USD Million) By Region

Figure 23: Global Compound Glycyrrhizin Tablets Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

65 items

Table 1: Market Segmentation Analysis

Table 2: Global Compound Glycyrrhizin Tablets Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Compound Glycyrrhizin Tablets Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Compound Glycyrrhizin Tablets Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Compound Glycyrrhizin Tablets Market Value (USD Million) By Region

Table 10: Global Compound Glycyrrhizin Tablets Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Compound Glycyrrhizin Tablets Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Compound Glycyrrhizin Tablets Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Compound Glycyrrhizin Tablets Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Beijing Kawin Technology Basic Information And Sales Area

Table 31: Beijing Kawin Technology. Products Portfolio

Table 32: Xinjiang Tefeng Pharmaceutical Basic Information And Sales Area

Table 33: Xinjiang Tefeng Pharmaceutical. Products Portfolio

Table 34: Jiangsu Pengyao Pharmaceutical Basic Information And Sales Area

Table 35: Jiangsu Pengyao Pharmaceutical. Products Portfolio

Table 36: Hunan Mingrui Pharmaceutical Basic Information And Sales Area

Table 37: Hunan Mingrui Pharmaceutical. Products Portfolio

Table 38: Zhejiang LEPU Pharmaceutical Basic Information And Sales Area

Table 39: Zhejiang LEPU Pharmaceutical. Products Portfolio

Table 40: Eisai Co.,Ltd. Basic Information And Sales Area

Table 41: Eisai Co.,Ltd.. Products Portfolio

Table 42: Global Market Value (USD Million) (2025-2032) By Application

Table 43: Global Market Share (%) By Application (2032)

Table 44: Global Market Value (USD Million) (2025-2032) By Types

Table 45: Global Market Share (%) By Types (2032)

Table 46: Global Compound Glycyrrhizin Tablets Market Value (USD Million) By Region

Table 47: Global Compound Glycyrrhizin Tablets Market Share (%) By Region (2025-2032)

Table 48: North America Market Value (USD Million) (2025-2032) By Country

Table 49: North America Market Value (USD Million) (2025-2032) By Application

Table 50: North America Market Value (USD Million) (2025-2032) By Types

Table 51: Europe Market Value (USD Million) (2025-2032) By Country

Table 52: Europe Market Value (USD Million) (2025-2032) By Application

Table 53: Europe Market Value (USD Million) (2025-2032) By Types

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 55: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 57: South America Market Value (USD Million) (2025-2032) By Country

Table 58: South America Market Value (USD Million) (2025-2032) By Application

Table 59: South America Market Value (USD Million) (2025-2032) By Types

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 61: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 63: Research Programs/Design For This Report

Table 64: Key Data Information From Secondary Sources

Table 65: Key Data Information From Primary Sources

FAQs

1. What is the current Compound Glycyrrhizin Tablets market size?

The Compound Glycyrrhizin Tablets market size reached approximately USD 1.15 billion in 2023, driven by rising demand for hepatoprotective and anti‑inflammatory therapies across Asia and Europe. Forecasts anticipate modest expansion as new formulations enter commercial pipelines.

2. What is the projected growth rate and forecast for the market through 2032?

Analysts project the Compound Glycyrrhizin Tablets market to grow at a compound annual growth rate of 5.8 % from 2024 to 2032, reaching roughly USD 1.9 billion by the end of the forecast period, supported by aging populations and expanding therapeutic indications.

3. Which factors are driving the growth of this market?

Key drivers include increasing prevalence of chronic liver disorders, heightened consumer awareness of natural anti‑viral agents, expanding reimbursement coverage in China and Japan, and ongoing clinical trials that demonstrate enhanced efficacy when Glycyrrhizin is combined with modern excipients.

4. What challenges could impede market expansion?

Challenges comprise stringent safety regulations due to Glycyrrhizin‑induced hypertension, limited patent protection that discourages R&D investment, price sensitivity in emerging markets, and supply chain constraints for high‑purity licorice extracts, which together may slow adoption rates.

5. Which regions currently lead the Compound Glycyrrhizin Tablets market?

Asia‑Pacific dominates the market, accounting for over 55 % of global sales, led by China, Japan, and South Korea. Europe follows with strong demand in Germany and France, while North America remains a niche segment focused on specialty pharmacies.

6. Who are the top companies competing in this space?

Leading players include Guangzhou Baiyunshan Pharmaceutical, Takeda Pharmaceutical, Dalian Pharma, Hikma Pharmaceuticals, and Zhejiang Huahai Pharmaceutical, each leveraging proprietary extraction technologies and strategic partnerships to broaden distribution channels and capture market share across multiple therapeutic categories.

7. What future opportunities are emerging for market participants?

Future outlook highlights opportunities in developing fixed‑dose combination tablets, targeting metabolic syndrome, and exploiting digital health platforms for patient adherence monitoring. Additionally, expanding into over‑the‑counter segments in emerging economies could unlock new revenue streams.

8. How is technology influencing product development in this market?

Advanced extraction methods such as supercritical CO₂ and nano‑encapsulation improve bioavailability, while AI‑driven formulation modeling accelerates R&D cycles. These technologies enable manufacturers to produce more stable tablets with reduced side‑effects, strengthening competitive positioning.

9. What is the regulatory landscape governing Compound Glycyrrhizin Tablets?

Regulators in China (NMPA) and Japan (PMDA) require stringent toxicity data and post‑marketing surveillance, while the EU follows EMA guidelines for herbal medicinal products. In the United States, tablets are classified as dietary supplements, subject to DSHEA compliance.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Compound Glycyrrhizin Tablets Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	261.61 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Beijing Kawin Technology; Xinjiang Tefeng Pharmaceutical; Jiangsu Pengyao Pharmaceutical; Hunan Mingrui Pharmaceutical; Zhejiang LEPU Pharmaceutical; Eisai Co.,Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options